Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Nrx - You Need To See This

FDA Approves Preservative-Free Generic Ketamine as Hospital Shortage Continues

The FDA approved a preservative-free generic ketamine injection from NRx Pharmaceuticals as hospitals continue managing a shortage that has persisted since 2018.

Medical Daily · Nov 1

NRx Pharmaceuticals Q1 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

MarketBeat · May 18

NRx Pharmaceuticals Targets Suicidal Bipolar Depression With Multidrug Therapy

NRx's NRX-101 shows promise in clinical trials, aims for FDA approval in 2024 to address unmet medical need.

Zenger · Jul 18, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

The Forgotten Nuclear Accidents at Chalk River

Workers who cleaned up after the disasters fear that their true effects will never be brought to light

The Walrus · Jul 13, 2022

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Benzinga · Jul 1, 2022

FDA Turns Down NRx Pharmaceuticals' Emergency Use Submission For Covid-19 Candidate

The U.S.

Benzinga · Jul 1, 2022

NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped

Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in the I-SPY COVID Trial of

Benzinga · Mar 31, 2022

Read news from The Economist, FT, and more,
with one subscription

NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant

NRx Pharmaceuticals (NASDAQ: NRXP) has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine can

Benzinga · Jan 27, 2022

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Jan 26, 2022

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19

NRx Pharmaceuticals (NASDAQ: NRXP) has

Benzinga · Jan 26, 2022

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its

Benzinga · Jan 18, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.